Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Pfizer-BioNTech COVID-19 Vaccine Booster Dose for Children Update

Last updated on

On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine as follows:

Authorization of a single booster dose for individuals 5 years through 11 years of age at least 5 months after completion of the primary series with the Pfizer-BioNTech COVID-19 vaccine.

The Texas Health and Human Services Commission allows for pharmacy benefit coverage of the Pfizer-BioNTech COVID-19 vaccine in compliance with the expanded use authorized by the FDA.

Contact with any comments or questions.